Evofem Biosciences (EVFM) Competitors $0.01 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSustainabilityTrends EVFM vs. KTTA, ATXI, APM, SNOA, CHRO, THAR, ARTL, GENE, CPHI, and SNPXShould you be buying Evofem Biosciences stock or one of its competitors? The main competitors of Evofem Biosciences include Pasithea Therapeutics (KTTA), Avenue Therapeutics (ATXI), Aptorum Group (APM), Sonoma Pharmaceuticals (SNOA), Chromocell Therapeutics (CHRO), Tharimmune (THAR), Artelo Biosciences (ARTL), Genetic Technologies (GENE), China Pharma (CPHI), and Synaptogenix (SNPX). These companies are all part of the "pharmaceutical products" industry. Evofem Biosciences vs. Pasithea Therapeutics Avenue Therapeutics Aptorum Group Sonoma Pharmaceuticals Chromocell Therapeutics Tharimmune Artelo Biosciences Genetic Technologies China Pharma Synaptogenix Pasithea Therapeutics (NASDAQ:KTTA) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, community ranking, media sentiment and dividends. Which has more risk & volatility, KTTA or EVFM? Pasithea Therapeutics has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of -0.78, indicating that its stock price is 178% less volatile than the S&P 500. Do insiders and institutionals hold more shares of KTTA or EVFM? 23.9% of Pasithea Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are held by institutional investors. 16.3% of Pasithea Therapeutics shares are held by company insiders. Comparatively, 0.2% of Evofem Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community favor KTTA or EVFM? Evofem Biosciences received 260 more outperform votes than Pasithea Therapeutics when rated by MarketBeat users. Likewise, 69.50% of users gave Evofem Biosciences an outperform vote while only 40.00% of users gave Pasithea Therapeutics an outperform vote. CompanyUnderperformOutperformPasithea TherapeuticsOutperform Votes240.00% Underperform Votes360.00% Evofem BiosciencesOutperform Votes26269.50% Underperform Votes11530.50% Is KTTA or EVFM more profitable? Pasithea Therapeutics has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Pasithea Therapeutics' return on equity of -81.57% beat Evofem Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Pasithea TherapeuticsN/A -81.57% -74.31% Evofem Biosciences -46.42%-91.97%-61.93% Does the media favor KTTA or EVFM? In the previous week, Pasithea Therapeutics and Pasithea Therapeutics both had 4 articles in the media. Pasithea Therapeutics' average media sentiment score of 0.76 beat Evofem Biosciences' score of 0.32 indicating that Pasithea Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pasithea Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evofem Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend KTTA or EVFM? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pasithea Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Evofem Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has stronger earnings & valuation, KTTA or EVFM? Evofem Biosciences has higher revenue and earnings than Pasithea Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPasithea Therapeutics$20K201.93-$15.96MN/AN/AEvofem Biosciences$11.39M0.09$52.98M-$0.62-0.02 SummaryPasithea Therapeutics beats Evofem Biosciences on 7 of the 13 factors compared between the two stocks. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get Evofem Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVFM vs. The Competition Export to ExcelMetricEvofem BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.02M$6.45B$5.03B$8.81BDividend YieldN/A8.11%5.16%4.06%P/E Ratio-0.0210.78135.4117.82Price / Sales0.09243.751,160.9774.56Price / CashN/A22.1633.5332.53Price / Book0.005.474.674.68Net Income$52.98M$153.61M$119.07M$226.08M7 Day PerformanceN/A-2.00%-1.83%-1.04%1 Month PerformanceN/A-7.46%-3.60%1.04%1 Year PerformanceN/A31.82%31.66%26.28% Evofem Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVFMEvofem Biosciences0.7996 of 5 stars$0.01flatN/A-85.3%$1.02M$11.39M-0.02120Gap UpKTTAPasithea Therapeutics1.3204 of 5 stars$3.19+1.3%N/A-50.4%$4.04M$20,000.000.003News CoverageGap UpHigh Trading VolumeATXIAvenue Therapeutics1.4956 of 5 stars$2.01+2.0%N/A-86.7%$3.84MN/A0.114Gap UpAPMAptorum Group0.3476 of 5 stars$0.74+1.4%N/A-54.6%$3.81M$431,378.000.0030Gap UpSNOASonoma Pharmaceuticals0.8248 of 5 stars$2.84-10.1%N/A+1,381.5%$3.81M$12.73M-0.57180High Trading VolumeCHROChromocell TherapeuticsN/A$0.62+14.8%N/AN/A$3.73MN/A0.004News CoverageTHARTharimmune0.8279 of 5 stars$2.50+2.9%N/A-96.1%$3.73MN/A0.002ARTLArtelo Biosciences3.2126 of 5 stars$1.15+3.6%$5.00+334.8%-8.7%$3.71MN/A-0.405Analyst RevisionGENEGenetic Technologies0.1043 of 5 stars$0.77flatN/AN/A$3.71M$5.03M0.0050CPHIChina PharmaN/A$0.19flatN/A-59.6%$3.69M$7.78M0.00231SNPXSynaptogenix2.0996 of 5 stars$2.65+10.0%$14.00+428.1%-59.2%$3.60MN/A0.004Negative NewsGap Up Related Companies and Tools Related Companies Pasithea Therapeutics Alternatives Avenue Therapeutics Alternatives Aptorum Group Alternatives Sonoma Pharmaceuticals Alternatives Chromocell Therapeutics Alternatives Tharimmune Alternatives Artelo Biosciences Alternatives Genetic Technologies Alternatives China Pharma Alternatives Synaptogenix Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EVFM) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evofem Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evofem Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
